登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC
ClinicalTrials.gov 上登记的一项肝细胞癌开放试验,由浙江大学医学院附属第二医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07422753,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Child-Pugh score ≤7.
入选标准第 8 条
Major surgical procedure (craniotomy, thoracotomy, or laparotomy) within 4 weeks prior to first dose, or unhealed wounds, ulcers, or fractures; tissue biopsy or other minor surgical procedures within 7 days prior to first dose (except venous catheter placement for intravenous infusion).
排除标准第 19 条
Subjects with a history or ongoing Hepatitis C virus (HCV) infection are eligible. HCV-treated subjects must have completed treatment at least 1 month prior to start of study treatment. Subjects with Hepatitis B virus (HBV) are eligible if they meet the following: Patients with HBV viral load ≥10,000 IU/mL must receive anti-HBV therapy concurrent with HCC treatment; subjects on anti-HBV therapy with viral load <10,000 IU/mL should continue the same therapy throughout study treatment. Subjects who are anti-HBc positive, HBsAg negative, anti-HBs negative or positive, and with HBV viral load <10,000 IU/mL do not require anti-HBV prophylaxis.
排除标准第 21 条
Active tuberculosis (TB), currently on anti-TB treatment or received anti-TB treatment within 1 year prior to first dose.
排除标准第 22 条
Prior treatment with any anti-PD-1 antibody, anti-PD-L1/L2 antibody, anti-CTLA-4 antibody, or other immunotherapy.
排除标准第 31 条
ECOG Performance Status score of 0\~1.
入选标准第 4 条
At least one measurable lesion according to RECIST 1.1 criteria.
入选标准第 9 条
Known human immunodeficiency virus (HIV) infection (positive HIV 1/2 antibodies), known syphilis infection.
排除标准第 23 条
Diagnosis of other malignancies within 5 years prior to first dose, except for radically treated basal cell carcinoma, squamous cell carcinoma of the skin, and/or carcinoma in situ. If diagnosis of other malignancy was more than 5 years prior, pathological/cytological diagnosis of recurrent/metastatic lesions is required.
排除标准第 30 条
Pregnant or breastfeeding female patients.
排除标准第 34 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;化验:血常规、肝肾功能。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07422753,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Sign and date a written informed consent form prior to the implementation of any trial-related procedures. Patients with clinically confirmed unresectable or metastatic hepatocellular carcinoma (HCC). Male or female, ≥18 years old, ≤75 years old. ECOG Performance Status score of 0\~1. Expected survival time >3 months. Barcelona Clinic Liver Cancer (BCLC) Stage B or C for unresectable HCC. Suitable for Transarterial Chemoembolization (TACE) treatment. Child-Pugh score ≤7. At least one measurable lesion according to RECIST 1.1 criteria.排除标准:Exclusion Criteria:
Previous histological/cytological confirmation of HCC with fibrolamellar, sarcomatoid, or cholangiocarcinoma components. History of liver transplantation or hepatic encephalopathy. Diffuse liver cancer. Inability to tolerate TACE or prior history of TACE treatment. Prior treatment with Transarterial Chemoembolization (TACE), Transarterial Embolization (TAE), or Transarterial Radioembolization (TARE). Prior systemic anti-tumor therapy or radiotherapy for HCC. Portal vein main trunk tumor thrombus without adequate collateral circulation, or concurrent involvement of the superior mesenteric vein; inferior vena cava tumor thrombus. Clinically symptomatic pleural effusion, ascites, or pericardial effusion requiring drainage. Any history of renal disease or nephrotic syndrome. History of esophageal or gastric variceal bleeding due to portal hypertension within the past 6 months; presence of severe (Grade 3) varices on endoscopy known within 3 months prior to first dose; evidence of portal hypertension (including splenomegaly on imaging) with high risk of bleeding as assessed by the investigator. Any life-threatening bleeding event within the past 3 months, requiring transfusion, surgery, local therapy, or continuous medication. Arterial or venous thromboembolic events within the past 6 months, including myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other severe thromboembolism. Except for catheter-related thrombosis from implanted ports or superficial venous thrombosis if stable under routine anticoagulation. Significant bleeding tendency or coagulopathy, or undergoing thrombolytic therapy. Prophylactic use of low-dose low molecular weight heparin (e.g., enoxaparin 40 mg/day) is allowed, but not vitamin K antagonists (e.g., warfarin). Requirement for long-term use of platelet function inhibitors such as aspirin, dipyridamole, or clopidogrel. Uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg despite optimal medical therapy), history of hypertensive crisis or hypertensive encephalopathy. Symptomatic congestive heart failure (New York Heart Association Class II-IV), symptomatic or poorly controlled arrhythmia, history of congenital long QT syndrome, or corrected QT interval (QTc) >500 ms on screening ECG (using Fridericia's formula). History of gastrointestinal perforation and/or fistula, intestinal obstruction (including incomplete obstruction requiring parenteral nutrition) within the past 6 months; extensive intestinal resection (partial colectomy or extensive small bowel resection with chronic diarrhea), Crohn's disease, ulcerative colitis, or chronic long-term diarrhea. Major surgical procedure (craniotomy, thoracotomy, or laparotomy) within 4 weeks prior to first dose, or unhealed wounds, ulcers, or fractures; tissue biopsy or other minor surgical procedures within 7 days prior to first dose (except venous catheter placement for intravenous infusion). History or current presence of pulmonary diseases such as pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, drug-induced pneumonia, or severe impaired lung function. Subjects with a history or ongoing Hepatitis C virus (HCV) infection are eligible. HCV-treated subjects must have completed treatment at least 1 month prior to start of study treatment. Subjects with Hepatitis B virus (HBV) are eligible if they meet the following: Patients with HBV viral load ≥10,000 IU/mL must receive anti-HBV therapy concurrent with HCC treatment; subjects on anti-HBV therapy with viral load <10,000 IU/mL should continue the same therapy throughout study treatment. Subjects who are anti-HBc positive, HBsAg negative, anti-HBs negative or positive, and with HBV viral load <10,000 IU/mL do not require anti-HBV prophylaxis. Active tuberculosis (TB), currently on anti-TB treatment or received anti-TB treatment within 1 year prior to first dose. Known human immunodeficiency virus (HIV) infection (positive HIV 1/2 antibodies), known syphilis infection. Active or poorly controlled severe infection. Severe infection within 4 weeks prior to first dose, including but not limited to hospitalization for infection complications, bacteremia, or severe pneumonia. Active autoimmune disease requiring systemic treatment (e.g., disease-modifying agents, corticosteroids, or immunosuppressants) within 2 years prior to first dose. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement for adrenal or pituitary insufficiency) is allowed. Known history of primary immunodeficiency. Subjects with only positive autoimmune antibodies should be evaluated by the investigator to confirm the absence of autoimmune disease. Use of immunosuppressive medication within 4 weeks prior to first dose, excluding intranasal, inhaled, topical corticosteroids, or systemic corticosteroids at physiologic doses (not exceeding 10 mg/day prednisone or equivalent). Temporary use of corticosteroids for conditions like asthma or COPD is allowed. Administration of a live attenuated vaccine within 4 weeks prior to first dose or planned during the study. Use of traditional Chinese medicine with anti-tumor indications or immunomodulatory drugs (including thymosin, interferon, interleukin; except for local use to control pleural or ascitic fluid) within 2 weeks prior to first dose. Uncontrolled/uncorrectable metabolic disorders, other non-malignant organ/systemic diseases, or cancer-related sequelae that could lead to higher medical risk and/or uncertainty in survival evaluation. Diagnosis of other malignancies within 5 years prior to first dose, except for radically treated basal cell carcinoma, squamous cell carcinoma of the skin, and/or carcinoma in situ. If diagnosis of other malignancy was more than 5 years prior, pathological/cytological diagnosis of recurrent/metastatic lesions is required. Prior treatment with any anti-PD-1 antibody, anti-PD-L1/L2 antibody, anti-CTLA-4 antibody, or other immunotherapy. Known allergy to Sintilimab, Bevacizumab, or their excipients, or history of severe hypersensitivity to other monoclonal antibodies. Treatment with other investigational agents within 4 weeks prior to first dose. Pregnant or breastfeeding female patients. Any other acute or chronic disease, psychiatric condition, or abnormal laboratory finding that, in the investigator's judgment, may increase the risk associated with study participation or study drug administration, or interfere with the interpretation of study results, and make the patient unsuitable for entry into this study.
引自 ClinicalTrials.gov, NCT07422753, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07422753,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。